A carregar...
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition
Antibodies that target immune checkpoint molecules, such as CTLA4, provide robust antitumor effects in a subset of patients. Unfortunately, not all patients respond to immune checkpoint inhibition, and some develop life-threatening immune-related adverse events (irAEs). The mechanisms that underlie...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6307975/ https://ncbi.nlm.nih.gov/pubmed/30530990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI125800 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|